Contact SCGE




Clinical Trial Report

Gene Therapy Trial Report

Summary

BS01 in Patients With Retinitis Pigmentosa


NCTID NCT04278131 (View at clinicaltrials.gov)
Description
Development Status Active
Indication Retinitis Pigmentosa
Disease Ontology Term DOID:10584
Compound Name BS01
Compound Description AAV2-CAG-ChronosFP-WPRE
Sponsor Bionic Sight LLC
Funder Type Industry
Recruitment Status
Recruiting
Enrollment Count 20
Results Posted Not Available

Therapy Information


Target Gene/Variant ChronosFP
Therapy Type Gene transfer
Therapy Route In-vivo
Mechanism of Action Overexpression of protective allele/gene
Route of Administration Intravitreal
Drug Product Type Viral vector
Target Tissue/Cell Retinal ganglion
Delivery System Viral transduction
Vector Type AAV2
Editor Type
Dose 1 Dose escalation with 4 levels, unknown concentrations
Dose 2
Dose 3
Dose 4
Dose 5

Study Record Dates


Current Stage Phase1, Phase2
Submit Date 2020-02-13
Completion Date 2029-12-30
Last Update 2023-05-03

Participation Criteria


Eligible Age >=18 Years
Standard Ages Adult, Older adult
Sexes Eligible for Study ALL

Locations


No.of Trial Sites 1
Locations United States

Regulatory Information


Has US IND True
FDA Designations Regenerative Medicine Advanced Therapy
Recent Updates Gene therapy product is coupled with a neural circuit, retinal prosthesis

Resources/Links